Novo Nordisk Partners With Anthropic to Accelerate Drug Development Using Claude AI
Sign in✓ Signed in
Novo Nordisk announced September 16 that it will deploy Anthropic's Claude AI models and Claude Science workbench to accelerate drug discovery and development, aiming to compress research timelines and maintain competitive footing in the high-stakes obesity drug market. The Danish pharmaceutical giant, facing declining market share in GLP-1 treatments, is betting on AI-driven science to regain momentum against rival Eli Lilly, whose Zepbound threatens Novo's Ozempic and Wegovy dominance.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...